Drug Profile
Revdofilimab - AbbVie
Alternative Names: ABBV-368; ABBV-368 I-O Monoclonal Antibody; PR-1628103Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator AbbVie
- Developer AbbVie; Aceragen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; OX40 receptor agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours; Squamous cell cancer
Most Recent Events
- 17 Jan 2023 Idera Pharmaceuticals is now called Aceragen
- 27 Oct 2022 AbbVie completes a Phase-I clinical trials in Squamous cell cancer (Combination therapy, First-line therapy, Metastatic disease, Recurrent) in France, Germany, Israel, Netherlands, Spain, USA (IV) (NCT04196283)
- 13 Apr 2022 Revdofilimab is still in phase I trial for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy) in USA, France and Taiwan (IV) (NCT03071757)